Dr Tolaney on Sequencing Available ADCs in Breast Cancer
December 8th 2023Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.
Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast Cancer
December 5th 2023Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.
HR+/HER2– Metastatic Breast Cancer Treatment Developments Continue to Unfold
October 19th 2023Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.
Novel Treatment Regimens Populate the HR+/HER2– and HER2+ Breast Cancer Armamentariums
September 14th 2023Yara Abdou, MD, discusses key updates in breast cancer research, including paradigm shifts on the horizon for trastuzumab deruxtecan, key data regarding capivasertib in the hormone receptor–positive, HER2-negative setting, and the importance of weighing the efficacy benefits of these agents with the risks for serious associated toxicities.
Expanding Breast Cancer Armamentarium Is Increasing the Quality of Individualized Care
August 8th 2023Michelina Cairo, MD, discusses key insights from trials including SONIA and CAPItello-291; how adverse effects inform treatment decisions across the breast cancer spectrum; and where the future is headed for ADCs and oral SERDs in patients with breast cancer.
Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets
July 18th 2023Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.
Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
June 1st 2023Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.